Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Partners with Atascosa Explor

18 Jun 2008 07:00

RNS Number : 9543W
ViaLogy PLC
18 June 2008
 



ViaLogy partners with Texas exploration group Atascosa to analyse onshore oil fields

Pasadena, 18 June:  ViaLogy PLC (LSE:VIY)a leading innovator of real-time network-centric signal processing platforms, announces that it has entered into an agreement with a Texas-based oil and gas exploration and production company, Atascosa Exploration LLC,  of San Antonio, to use ViaLogy's  unique technology, QuantumRD™, to analyse seismic data for more accurate definition of the extent and density of underground oil reservoirs prior to the commencement of drilling. The data analysis on three prospective Texas-based well sites will begin immediately. Complete results will be delivered by ViaLogy to Atascosa within three weeks, and exploratory drillinto prove the technology will commence soon afterwards.

The problems of predicting oil traps from coarse seismic data analysis have plagued the oil and gas industry for decades. Pinpoint accuracy is essentialPredictions that are just a few feet out can waste millions of dollars.

QuantumRD applies ViaLogy's patented and proven Quantum Resonance Interferometry (QRI™) technology to analyse coarse 2D and 3D seismic signals and extract more detailed and accurate information than has hitherto been possibleFor the first three pilot wells ViaLogy and Atascosa have reached a non-operating interest participation arrangement, which is based on production in excess of their oil trap estimates prior to the QuantumRD analysis. Assuming that the analysis proves successful the two companies have agreed to form a joint venture company or other business arrangement for the commercialisation of Quantum RD within the United States.

Atascosa CEO, John D. Mullins, said, "We are delighted that Atascosa can take the lead in bringing ViaLogy's technology to market. A successful pilot should result in the widespread use of QuantumRD throughout the industry."

 ViaLogy CEO, Robert W. Dean, said, "QuantumRD should increase the accuracy of existing and future seismic petroleum data reduce false positives about where to drill, and have a significant impact on the oil exploration industry. It should also offer ViaLogy opportunity to expand its sales in an adjacent market. Atascosa is the ideal partner for us."

Mr. Dean pointed out that, if the pilot analysis proves successful, the potential for QuantumRD™ iextensive According to Energy Information Administration (EIA)'s 2006 Annual Report, US had over 21 billion barrels of proven oil reserves. Most of the newer discoveries are in smaller fields. However, the number of newer oilfield discoveries has declined from 1400 in 2001 to 30 by 2006Just over 40 new reservoirs were discovered in known US fields in 2006 based on EIA released numbers.

"Due to the high cost of oil today, producers can now afford to bring on line reserves that were previously passed over because of production rate or quantity or quality of reservoir. QuantumRD shines in this environment because it allows a clear definition of reservoir size and shape. Based on EIA released data, wells in the US are now averaging over 5700 feet in depth. As the cost to drill wells between 5,000 and 12,000 feet is now approximately $1.5 million to $4 million dollars, making an accurate prediction of reservoir characteristics is even more of an economic necessity. ViaLogy's preferred business model is ainterpretation fee and overriding royalty interest (ORRI).  Our ability to accurately predict reservoir size and quality should become a required part of the search for hydrocarbons here and abroad."

  For Further Information please contact

ViaLogy

Robert W Dean, President & CEO - US +1 626-296-6337 (mobile: +1 703-589-3807)

Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 

Atascosa Exploration LLC

John D. Mullins, CEO (+1 210-402-3656).

Nominated Advisor (Seymour Pierce)

Mark Percy +44 (0) 20-7107-8000 

PR Consultants - Redleaf Communications

Samantha Robbins / Anna Dunkin +44 (0) 20-7822-0200

 

About ViaLogy: Network Centric Signal Processing.

ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications. ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geoseismology. Vialogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential. ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noise background and clutter. This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications. For more information, visit our website at www.vialogy.com. 

Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied. 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRFDLLFVQBXBBD
Date   Source Headline
14th Dec 20217:00 amRNSHalf-year Report
6th Dec 20217:00 amRNSNotice of Half-year results
18th Nov 20217:00 amRNSDPYD screening recommended in Spain
28th Oct 20217:00 amRNSRanger® Technology to be presented at Labroots
26th Oct 20217:00 amRNSHalf-year Trading update
29th Sep 20217:00 amRNSResult of AGM
28th Sep 20213:00 pmRNSAGM update
28th Sep 20217:00 amRNSAGM Statement
15th Sep 20217:00 amRNSShare option awards
1st Sep 20217:00 amRNSISO 15189:2012 accreditation received
1st Sep 20217:00 amRNSNotice of AGM and Annual Report 2021
19th Aug 202112:04 pmRNSCOVID-19 Surge testing contract
11th Aug 20217:01 amRNSEarn-out Milestone, Issue of Equity & TVR
11th Aug 20217:00 amRNSAudited Final results&unaudited Q1 business update
6th Aug 20217:00 amRNSConfirmation of Results Date
23rd Jul 20217:00 amRNSNotice of Results
1st Jul 202111:09 amRNSHolding(s) in Company
21st Jun 20217:00 amRNSSecond Strategic Partner for Coastal Genomics
18th Jun 20217:00 amRNSContract Award: DPYD testing kits for NHS Wales
17th Jun 20214:32 pmRNSExercise of Options
9th Jun 20217:00 amRNSMulti-year licence and supply agreement
21st May 20214:30 pmRNSDirector/PDMR Shareholding
19th May 20217:00 amRNSDistribution Partnership
18th May 20217:00 amRNSLaunch of IONA Care NIPT service offering
17th May 20217:00 amRNSFurther testing service agreement for MHC
29th Apr 20217:00 amRNSFull year Trading update
26th Apr 20217:00 amRNSFurther National Microbiology Framework awards
19th Apr 20211:21 pmRNSFurther National Microbiology Framework contract
19th Apr 20217:00 amRNSNational Framework contract award
12th Apr 20217:00 amRNSEarn-out Milestone, Issue of Equity & TVR
6th Apr 20212:43 pmRNSTesting service agreement with MyHealthCheckedplc
6th Apr 20211:54 pmRNSAgreement with Boots for COVID-19 sample kits
29th Mar 20214:00 pmRNSCOVID-19 update
23rd Mar 20217:00 amRNSShare option exercises and awards
19th Mar 20217:00 amRNSTwin Pregnancy study published using IONA® Test
17th Mar 20217:00 amRNSAppointment of VP of Sales North America
11th Mar 20217:00 amRNSYourgene Genomic Services portfolio expansion
1st Mar 20217:00 amRNSFirst US Supply Agreement
22nd Feb 20217:00 amRNSPartnership with NPH
10th Feb 202110:51 amRNSCorrection: Director / PDMR Shareholding
10th Feb 20217:00 amRNSDirector/PDMR Shareholding
8th Feb 20217:00 amRNSTrading update
13th Jan 20217:00 amRNSDPYD screening recommended in Belgium
11th Jan 20217:00 amRNSClarigene® SARS-CoV-2 Product Update
8th Jan 20217:00 amRNSIssue of Share Options
24th Dec 20207:00 amRNSCOVID-19 update
17th Dec 20207:00 amRNSHalf-year Report
15th Dec 20207:00 amRNSNotice of Half-year Results
2nd Dec 20207:00 amRNSDPYD kits recommended by NHS England
2nd Dec 20207:00 amRNSGenomic testing service launch and Change of name

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.